RESULTS OF A RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF PATUPILONE (P) VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN TAXANE/PLATINUM REFRACTORY/RESISTANT PATIENTS WITH RECURRENT OVARIAN, FALLOPIAN, OR PERITONEAL CANCER

Abstract

Abstract is not available.